Dong Na, Zhang Chen, Zhang Qiao, Bao Sa, Hu Yunfan, Xu Haichao, Dai Peng, Li Caiyan, Li Shengcun, Wu Ping, Xu Junpeng, Cai Xiaojun, Wang Zhouguang, Luo Lihua
School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
J Nanobiotechnology. 2025 Jul 28;23(1):547. doi: 10.1186/s12951-025-03597-3.
Oral ulcer (OU) is one of the most common mucosal diseases, yet current drug treatments yield unsatisfactory outcomes. Persistent inflammatory responses and insufficient angiogenesis are the two major obstacles to OU healing. Recently, stem cell-based therapies, particularly mesenchymal stem cells (MSCs), have shown great regenerative potential through their anti-inflammatory and proangiogenic properties in OU treatment. However, they still face challenges, such as low cell survival rates, uncontrolled differentiation, and immune rejection. Meanwhile, a humid and highly dynamic oral environment degrades and dilutes biological drugs via saliva, thereby reducing their bioavailability during OU repair. To address these limitations, we developed an injectable fibrinogen/thrombin (FT) hydrogel encapsulating cell lysate (CL) derived from the stem cells of human exfoliated deciduous teeth (SHEDs). The SHED-derived CL retained the therapeutic properties of SHEDs while eliminating risks associated with cell transplantation. The FT hydrogel exhibited excellent biocompatibility, controlled CL release, and strong adhesion to oral wounds (> 24 h). In vitro, the FT/CL hydrogel polarized macrophages toward the anti-inflammatory M2 phenotype (upregulating CD206 and Arg1 expression) and suppressed pro-inflammatory M1 markers (iNOS and TNF-α) secretion. It also significantly enhanced tube formation, with a 2.5-fold increase in luminal length and 3.7-fold increase in the number of tubes compared with that in the control group. In a rat OU model, the FT/CL group showed accelerated ulcer healing, clearly reducing the inflammatory response on day 3 and nearly restoring epithelial integrity by day 5. Additionally, the FT/CL hydrogel effectively inhibited inflammatory infiltration and alleviated pain at the wound site, with effects similar to those of the positive control (the watermelon frost group). Furthermore, the FT/CL hydrogel promoted cell proliferation in the epithelial tissue and enhanced vascular remodeling near the basement membrane, thereby accelerating ulcer healing. Therefore, the FT/CL hydrogel promotes ulcer healing by regulating inflammation, promoting cell proliferation, and enhancing angiogenesis. This study provides a safe and efficient method for enhancing the therapeutic application of SHED-derived CL. The findings suggest that CL-based cell-free therapy may be a promising strategy for future clinical use in ulcer and chronic wound healing.
口腔溃疡(OU)是最常见的黏膜疾病之一,但目前的药物治疗效果并不理想。持续的炎症反应和血管生成不足是OU愈合的两大障碍。最近,基于干细胞的疗法,特别是间充质干细胞(MSCs),通过其在OU治疗中的抗炎和促血管生成特性显示出巨大的再生潜力。然而,它们仍然面临挑战,如细胞存活率低、分化不受控制和免疫排斥。同时,潮湿且高度动态的口腔环境会通过唾液降解和稀释生物药物,从而降低其在OU修复过程中的生物利用度。为了解决这些局限性,我们开发了一种可注射的纤维蛋白原/凝血酶(FT)水凝胶,其包裹了源自人脱落乳牙(SHEDs)干细胞的细胞裂解物(CL)。源自SHED的CL保留了SHED的治疗特性,同时消除了与细胞移植相关的风险。FT水凝胶表现出优异的生物相容性、可控的CL释放以及对口腔伤口的强粘附性(> 24小时)。在体外,FT/CL水凝胶使巨噬细胞向抗炎的M2表型极化(上调CD206和Arg1表达),并抑制促炎M1标志物(iNOS和TNF-α)的分泌。它还显著增强了血管生成,与对照组相比,管腔长度增加了2.5倍,管数量增加了3.7倍。在大鼠OU模型中,FT/CL组显示溃疡愈合加速,在第3天明显减轻炎症反应,到第5天几乎恢复上皮完整性。此外,FT/CL水凝胶有效抑制炎症浸润并减轻伤口部位的疼痛,效果与阳性对照(西瓜霜组)相似。此外,FT/CL水凝胶促进上皮组织中的细胞增殖,并增强基底膜附近的血管重塑,从而加速溃疡愈合。因此,FT/CL水凝胶通过调节炎症、促进细胞增殖和增强血管生成来促进溃疡愈合。本研究提供了一种安全有效的方法来增强源自SHED的CL的治疗应用。研究结果表明,基于CL的无细胞疗法可能是未来溃疡和慢性伤口愈合临床应用的一种有前景的策略。